Enanta Pharmaceuticals, Inc. (ENTA)
12.50
+0.40
(+3.31%)
USD |
NASDAQ |
Oct 09, 16:00
Enanta Pharmaceuticals Price to Book Value : 3.602 for Oct. 9, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 3.602 |
| October 08, 2026 | 3.486 |
| October 07, 2026 | 3.564 |
| October 06, 2026 | 3.506 |
| October 05, 2026 | 3.630 |
| October 02, 2026 | 3.734 |
| October 01, 2026 | 3.700 |
| September 30, 2026 | 3.798 |
| September 29, 2026 | 3.642 |
| September 28, 2026 | 3.635 |
| September 25, 2026 | 3.423 |
| September 24, 2026 | 3.458 |
| September 23, 2026 | 3.443 |
| September 22, 2026 | 3.578 |
| September 21, 2026 | 3.489 |
| September 18, 2026 | 3.515 |
| September 17, 2026 | 3.607 |
| September 16, 2026 | 3.659 |
| September 15, 2026 | 3.541 |
| September 14, 2026 | 3.780 |
| September 11, 2026 | 3.734 |
| September 10, 2026 | 3.659 |
| September 09, 2026 | 3.815 |
| September 08, 2026 | 3.890 |
| September 04, 2026 | 4.057 |
| Date | Value |
|---|---|
| September 03, 2026 | 4.040 |
| September 02, 2026 | 4.060 |
| September 01, 2026 | 3.892 |
| August 31, 2026 | 3.841 |
| August 28, 2026 | 3.918 |
| August 27, 2026 | 3.976 |
| August 26, 2026 | 4.077 |
| August 25, 2026 | 4.057 |
| August 24, 2026 | 4.062 |
| August 21, 2026 | 3.881 |
| August 20, 2026 | 3.783 |
| August 19, 2026 | 3.892 |
| August 18, 2026 | 3.832 |
| August 17, 2026 | 3.697 |
| August 14, 2026 | 3.792 |
| August 13, 2026 | 3.872 |
| August 12, 2026 | 3.890 |
| August 11, 2026 | 3.895 |
| August 10, 2026 | 3.979 |
| August 07, 2026 | 3.968 |
| August 06, 2026 | 3.844 |
| August 05, 2026 | 3.809 |
| August 04, 2026 | 3.838 |
| August 03, 2026 | 3.731 |
| July 31, 2026 | 3.630 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Perspective Therapeutics, Inc. | 0.9264 |
| Coherus Oncology, Inc. | 2.691 |
| BridgeBio Pharma, Inc. | -- |
| RenovoRx, Inc. | 6.432 |
| ACADIA Pharmaceuticals, Inc. | 2.612 |
Price to Book Value Related Metrics
| PS Ratio | 5.184 |
| Price | 12.50 |
| Earnings Yield | -19.29% |
| Market Cap | 364.00M |